Rekvina Laboratories Ltd

Rekvina Laboratories Limited has responded to stock exchange queries regarding significant price movements in its securities. The company stated it is unaware of any specific information, event, or impending announcement that could be influencing the price, beyond what has already been disclosed. Rekvina confirmed its compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and asserted that no undisclosed price-sensitive information or material events are being withheld. The company attributes the price and volume fluctuations to market-driven factors.

Rekvina Laboratories Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026. The Board of Directors also approved the appointment of Mr. Surbhit Shah as the Chairman of the Board and received the Limited Review Report from statutory auditors Y. M. Shah & Co. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS 34).

Rekvina Laboratories Ltd announced the outcome of its Board Meeting held on August 13, 2026. The board approved the standalone un-audited financial results for the quarter ended June 30, 2026, along with the limited review report from the statutory auditors. Additionally, Mr. Surbhit Shah was appointed as the Chairman of the Board of Directors. The meeting commenced at 3:00 PM and concluded at 3:30 PM.

Rekvina Laboratories Ltd has approved the allotment of 50,87,750 equity shares on a preferential basis. This includes 46,27,750 shares issued for consideration other than cash, as part of the acquisition of 100% equity in Radiant Parenterals Limited. The remaining 4,60,000 shares were allotted for a cash consideration of ₹46,00,000. The acquisition of Radiant Parenterals Limited will make it a wholly-owned subsidiary of Rekvina Laboratories. The shares were issued at a premium, with a face value of ₹5 and an issue price of ₹10 per share.

Rekvina Laboratories Ltd has announced that its Board of Directors will convene on August 13, 2026, to consider and approve the Unaudited Standalone Financial Results for the quarter ending June 30, 2026, prepared under Indian Accounting Standards (Ind AS). The company has also informed its designated persons about the closure of the trading window for company shares from July 01, 2026, until 48 hours after the financial results are publicly disclosed, in compliance with SEBI regulations on insider trading.

Vivro Financial Services Pvt Ltd, acting as the Manager to the Open Offer for Rekvina Laboratories Ltd, has submitted a Pre-Offer Advertisement to BSE. This advertisement, published on June 30, 2026, complies with Regulation 18(7) of SEBI SAST Regulations. It serves as a corrigendum to the Detailed Public Statement and provides details about the open offer for up to 28,90,700 equity shares, representing 26% of the expanded share capital. The offer is made by Surblhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer price is ₹10 per equity share, and the tendering period is from July 1, 2026, to July 14, 2026. The Committee of Independent Directors has deemed the offer price fair and reasonable.

Rekvina Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the company's financial results for the quarter ended June 30, 2026. The specific date for the board meeting to approve these financial results will be communicated separately. This measure is in compliance with SEBI regulations and the company's internal code of conduct regarding insider trading.

Rekvina Laboratories Limited has submitted the Recommendations of the Committee of Independent Directors (IDC) regarding the open offer made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The open offer is to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at ₹10 per share, totaling ₹2,89,01,000. The IDC has deemed the offer price fair and reasonable, advising public shareholders to independently evaluate and make informed decisions. The recommendations were published in newspapers on June 25, 2026.

Rekvina Laboratories Ltd announced that its Committee of Independent Directors (IDC) met on June 24, 2026, to provide recommendations on an open offer. The offer, made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel, aims to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at ₹10 per share. The total consideration is ₹2,89,01,000. The IDC has deemed the offer price fair and reasonable in accordance with SEBI SAST Regulations, though public shareholders are advised to make their own informed decisions. The committee reviewed various documents including the Public Announcement, Detailed Public Statement, and valuation reports.

Rekvina Laboratories Ltd has received a Letter of Offer from Vivro Financial Services Private Limited concerning an open offer to the public shareholders. The offer is being made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at a price of ₹10 per share. This open offer is in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The offer is not conditional on a minimum acceptance level.